CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
Abstract Anticancer combination therapy has been developed to increase efficacy by enhancing synergy. Patient-derived xenografts (PDXs) have emerged as reliable preclinical models to develop effective treatments in translational cancer research. However, most PDX combination study designs focus on s...
Main Authors: | Licai Huang, Jing Wang, Bingliang Fang, Funda Meric-Bernstam, Jack A. Roth, Min Jin Ha |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-16933-6 |
Similar Items
-
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
by: Shahrokh Abdolahi, et al.
Published: (2022-05-01) -
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting
by: Ann L. Oberg, et al.
Published: (2021-04-01) -
Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX)
by: Joan E. Malcolm, et al.
Published: (2019-03-01) -
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
by: Seiji Okada, et al.
Published: (2019-08-01) -
SENTINEL LYMPH NODE DISSECTION CONTROVERSIES
by: Funda Meriç Bernstam
Published: (2005-01-01)